13F Holdings
中文EN

CBLL Ceribell, Inc.

Electromedical & Electrotherapeutic Apparatus · Nasdaq · SEC CIK 1861107 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY31.3%
TTM net income YoY-40.8%
TTM EPS YoY-467.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin89.3%
Operating margin-69.8%
Net margin-68.0%
FCF margin-51.9%
EBITDA margin-68.9%

Returns

ROE-52.5%
ROA-41.5%
ROIC (approx.)-55.5%
Asset turnover0.61x

Leverage & solvency

Liabilities / assets24.8%
Debt / equity0.00x
Current ratio8.18x
Interest coverage-47.39x

Cash quality & payout

Operating cash flow / net income0.76x
Accruals ratio-10.0%
Payout ratio—
Capex / revenue0.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$29.34M$28.10M$26.49M$24.78M$22.59M$21.20M$20.49M$18.53M
Cost of revenue$3.00M$2.16M$3.37M$3.14M$2.65M$2.52M$2.48M$2.30M
Gross profit$26.34M$25.94M$23.12M$21.64M$19.94M$18.68M$18.01M$16.24M
R&D expense$7.40M$6.75M$6.16M$5.06M$4.98M$4.85M$4.25M$3.91M
SG&A expense$14.45M$14.76M$15.32M$12.12M$11.04M$11.36M$9.94M$9.97M
Operating income-$20.55M-$19.98M-$20.75M-$14.60M-$14.65M-$14.95M-$14.21M-$12.88M
Interest expense$267,000$438,000$434,000$462,000$480,000$477,000$471,000$499,000
Pretax income-$21.35M-$19.27M-$19.74M-$13.53M-$13.46M-$13.64M-$12.78M-$12.58M
Income tax$0$0—$0$0$0——
Net income-$21.35M-$19.27M-$19.74M-$13.53M-$13.46M-$13.64M-$12.78M-$12.58M
EBITDA-$20.35M-$19.78M-$20.51M-$14.30M-$14.35M-$14.75M-$13.87M-$12.52M
EPS (basic)-0.55-0.51-0.52—-0.37-0.38-0.36—
EPS (diluted)-0.55-0.51-0.52—-0.37-0.38-0.36—
Weighted avg. shares (diluted)38.50M38.03M37.66M—36.81M36.29M35.88M—
Balance sheet
Cash & equivalents$41.99M$32.66M$45.25M$40.48M$23.74M$40.14M$153.36M$194.37M
Short-term investments$75.48M$96.60M$95.93M$118.78M$144.80M$137.29M$29.34M—
Receivables$17.79M$15.99M$15.71M$15.05M$12.23M$12.31M$11.30M$10.88M
Inventory$6.96M$6.74M$6.90M$7.29M$6.02M$6.00M$6.55M$6.94M
Current assets$147.44M$157.85M$168.91M$186.72M$191.81M$199.79M$205.42M$217.27M
PP&E, net$1.77M$1.76M$1.93M$2.03M$2.06M$2.10M$2.12M$2.31M
Total assets$156.37M$166.35M$178.08M$195.80M$199.53M$207.69M$213.47M$225.41M
Current liabilities$18.03M$17.20M$16.18M$19.19M$15.17M$15.01M$11.83M$12.99M
Total liabilities$38.83M$38.03M$37.27M$40.47M$35.44M$35.53M$32.59M$34.25M
Shareholders' equity$117.54M$128.31M$140.81M$155.34M$164.08M$172.16M$180.88M$191.16M
Shares outstanding38.82M38.22M37.86M37.49M37.05M36.60M35.90M35.85M
Cash flow statement
Operating cash flow-$13.08M-$12.86M-$19.30M-$10.77M-$11.10M-$7.53M-$11.40M-$9.97M
Capital expenditure$100,000$17,000$125,000$179,000$369,000$71,000$148,000$357,000
Free cash flow-$13.18M-$12.88M-$19.42M-$10.95M-$11.47M-$7.60M-$11.55M-$10.33M
Investing cash flow$20.82M-$606,000$22.44M$26.11M-$6.94M-$107.69M-$29.61M-$493,000
Financing cash flow$1.58M$880,000$1.63M$1.40M$1.64M$2.01M$2,000$190.73M
Depreciation & amortization$200,000$200,000$239,000$291,000$300,000$200,000$335,000$364,000
Stock-based compensation$7.10M$6.00M$3.72M$3.36M$3.35M$3.17M$2.35M$2.20M

Free plan shows the latest 8 periods; Pro shows all 15 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.